---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015132"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:38:23.896838+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics raises ~$2.39M in PIPE financing from V-Co 3; includes conversion of $1.4M bridge note

## Summary
- Sold 1,353,625 shares, pre-funded warrant for 429,957 shares, and Series A/B warrants for 1,783,582 each at $1.34 per unit.
- Cash proceeds of $850,000; $1,400,000 bridge note converted; gross proceeds $2,390,000.
- Series A/B warrants exercisable at $1.09 (2 and 5 year terms); pre-funded warrant exercisable at $0.0001.
- Company must file resale registration statement within 45 days and use best efforts for effectiveness within 90 days.
- Net proceeds to be used for general working capital purposes.

## SEC filing metadata
- accession: 0001493152-26-015132
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015132
- JSON: https://secwatch.observer/filing/0001493152-26-015132.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015132.txt

## Source-grounded claims
- claim_id: f88cf4009070e3eea0a98712e1d566dc0f97f338
  claim: Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with V-Co Investors 3 LLC valued at $850,000 cash proceeds; $1,400,000 conversion of bridge note; total purchase price $1.34 per share (effective 2026-03-31).
  evidence_excerpt: On March 31, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 3 LLC, a Wyoming limited liability company (“ V-Co 3 ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.